Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, Yesterday

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Stephen Padilla, 12 Sep 2019
Overweight and obesity show an inverse relationship with acne in a dose-dependent manner in young adults, according to a recent study. This suggests that the metabolically active adipose tissue plays a protective role in acne.

HCV tied to greater risks of death, sick sinus syndrome than HBV infections

17 Aug 2019
Authorities in Malaysia have approved a compulsory license for Hepatitis C treatment, which allows for cheaper generic medication to be produced without the drug patent holder’s consent.

The risks of death and sick sinus syndrome are higher in patients with hepatitis C (HCV) than hepatitis B (HBV) virus infections, reports a recent Taiwan study.

Accessing electronic medical records from the National Health Insurance Research Database, researchers identified 5,480 HCV (mean age, 52.7±15.1 years; 49.5 percent male) and 5,480 HBV (mean age, 52.5±14.5 years; 50.1 percent male) patients. Primary outcomes were the occurrence of cardiac arrhythmias and all-cause mortality. Those with concomitant HBV and HCV, alcohol or drug abuse, cardiomyopathy, and thyroid disease, among other comorbidities, were excluded.

Patients with HCV were significantly more likely to die than their HBV counterparts (hazard ratio [HR], 1.35, 95 percent CI, 1.16–1.58; p<0.001). The likelihood of developing sick sinus syndrome was likewise significantly elevated in HCV participants (HR, 1.77, 1.07–2.91; p=0.025).

On the other hand, while atrial fibrillation occurred more frequently in the HCV group (2.24 percent vs 1.72 percent), the between-group difference in risk was only marginally significant (HR, 1.25, 0.98–1.59; p=0.07).

The effects of HCV infection on the risk of mortality and sick sinus syndrome were robust to subgroup analysis and did not meaningfully change across different strata of gender, age and comorbidities.

The occurrences of supraventricular tachycardia, atrial flutter, ventricular tachycardia, ventricular fibrillation and heart block were all comparable between the two groups.

Important limitations of the study included the use of claims-based epidemiological data and the racially homogenous study population, which might limit the generalizability of the findings, said researchers. Future studies should aim to address such weaknesses.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, Yesterday

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Stephen Padilla, 12 Sep 2019
Overweight and obesity show an inverse relationship with acne in a dose-dependent manner in young adults, according to a recent study. This suggests that the metabolically active adipose tissue plays a protective role in acne.